Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Multiple Myeloma 307Recurrence 64Neoplasms 32Neoplasms, Plasma Cell 17Lymphoma, Non-Hodgkin 14Carcinoma, Non-Small-Cell Lung 13Prostatic Neoplasms 12Vomiting 11Neoplasm Metastasis 8Leukemia, Myeloid, Acute 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Nausea 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma 7Ovarian Neoplasms 6Immunoglobulin Light-chain Amyloidosis 6Hematologic Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Paraproteinemias 5Lung Neoplasms 5Leukemia 5Small Cell Lung Carcinoma 4Renal Insufficiency 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Plasmacytoma 4Lymphoma, Follicular 4Hematologic Diseases 4Leukemia, Plasma Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3

Interventions

Doxorubicin 5Dacarbazine 5Trabectedin 3belinostat 2PTC596 2toripalimab 1soblidotin 1rucaparib 1ridaforolimus 1reolysin 1pembrolizumab 1pazopanib 1olaratumab 1futibatinib 1cixutumumab 1cemiplimab 1anlotinib 1Tablets 1TTI-621 1Rosuvastatin Calcium 1PM 01183 1Midazolam 1Injections 1Imatinib Mesylate 1Ifosfamide 1Fluorouracil 1Erlotinib Hydrochloride 1Docetaxel 1Digoxin 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leiomyosarcoma × Dexamethasone × Clear all
NCT00060944 2014-09-08

A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
271 enrolled 13 charts
Sarcoma

Leiomyosarcoma, Liposarcoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡